Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730489) titled 'A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan' on July 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Condition:
Colorectal Cancer
Intervention:
Drug: BL-M07D1
Drug: Regorafenib
Drug: Fruquintinib
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 2026
Target Samp...